Literature DB >> 12620643

Activated/effector CD4+ T cells exacerbate acute damage in the central nervous system following traumatic injury.

Dominic Fee1, Amanda Crumbaugh, Thomas Jacques, Benjamin Herdrich, Diane Sewell, David Auerbach, Shari Piaskowski, Michael N Hart, Matyas Sandor, Zsuzsa Fabry.   

Abstract

CD4(+) helper T cells (Th) have been demonstrated to participate in the chronic phase of traumatic injury repair in the central nervous system (CNS). Here, we show that CD4(+) T cells can also contribute to the severity of the acute phase of CNS traumatic injury. We compared the area of tissue damage and the level of cellular apoptosis in aseptic cerebral injury (ACI) sites of C57BL/6 wild type and RAG1(-/-) immunodeficient mice. We demonstrate that ACI is attenuated in RAG1(-/-) mice compared to C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(low)CD44(high) activated/effector T cells 24 h prior to ACI into RAG1(-/-) mice resulted in a significantly enhanced acute ACI that was comparable to ACI in the C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(high)CD44(low) naive/non-activated T cells did not increase ACI in the brains of RAG1(-/-) mice. T cell inhibitory agents, cyclosporin A (CsA) and FK506, significantly decreased ACI-induced acute damage in C57BL/6 mice. These results suggest a previously undescribed role for activated/effector CD4(+) T cells in exacerbating ACI-induced acute damage in the CNS and raise a novel possibility for acute treatment of sterile traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620643     DOI: 10.1016/s0165-5728(03)00008-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

Review 1.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

Review 3.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury.

Authors:  Dustin J Donnelly; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

Review 4.  Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury.

Authors:  D P Ankeny; P G Popovich
Journal:  Neuroscience       Date:  2008-07-04       Impact factor: 3.590

5.  A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice.

Authors:  Chuang Gao; Yu Qian; Jinhao Huang; Dong Wang; Wanqiang Su; Peng Wang; Linyue Guo; Wei Quan; Shuo An; Jianning Zhang; Rongcai Jiang
Journal:  Mol Neurobiol       Date:  2016-12-06       Impact factor: 5.590

6.  Neurotoxic or Neuroprotective? Current Controversies in SCI-Induced Autoimmunity.

Authors:  Jonah W Saltzman; Ricardo Battaglino; Helen Stott; Leslie R Morse
Journal:  Curr Phys Med Rehabil Rep       Date:  2013-09

7.  CD4+ T-Cell Responses Mediate Progressive Neurodegeneration in Experimental Ischemic Retinopathy.

Authors:  Thi Hong Khanh Vu; Huihui Chen; Li Pan; Kin-Sang Cho; Djoeke Doesburg; Eric F Thee; Nan Wu; Elisa Arlotti; Martine J Jager; Dong Feng Chen
Journal:  Am J Pathol       Date:  2020-05-08       Impact factor: 4.307

Review 8.  Stroke and T-cells.

Authors:  Thiruma V Arumugam; D Neil Granger; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

9.  Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist.

Authors:  Diane L Sewell; Brendon Nacewicz; Frances Liu; Sinarack Macvilay; Anna Erdei; John D Lambris; Matyas Sandor; Zsuzsa Fabry
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

10.  Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.

Authors:  Emily K Reinke; Jangeun Lee; Alla Zozulya; Jozsef Karman; William A Muller; Matyas Sandor; Zsuzsanna Fabry
Journal:  J Neuroimmunol       Date:  2007-04-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.